Drugs / Nidufexor
Nidufexor
also known as
4-[(N-BENZYL-1-{8-CHLORO-1-METHYL-1H,4H-CHROMENO[4,3-C]PYRAZOL-3-YL}FORMAMIDO)METHYL]BENZOIC ACID · LMB763 · NIDUFEXOR (LMB-763)
Small molecule targets NR1H4 via activation
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03804879 | Dec 2018 → May 2021 | diabetic kidney disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02913105 | Oct 2016 → Sep 2018 | metabolic dysfunction-associated steatohepatitis | Novartis Pharmaceuticals | Terminated | Met primary |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nidufexor | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03804879 ↗ |
| Known as | 4-[(N-BENZYL-1-{8-CHLORO-1-METHYL-1H,4H-CHROMENO[4,3-C]PYRAZOL-3-YL}FORMAMIDO)METHYL]BENZOIC ACID | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297626 ↗ |
| Known as | LMB763 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02913105 ↗ |
| Known as | NIDUFEXOR (LMB-763) | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297626 ↗ |
| Action | Activate | “Bile acid receptor FXR agonist” CHEMBL4297626 ↗ |
| Modality | Small molecule | — CHEMBL4297626 ↗ |
| Route | Oral | “Oral dose once daily for 12 weeks (84 days)” NCT02913105 ↗ |
| Target | NR1H4 | “Bile acid receptor FXR agonist” CHEMBL4297626 ↗ |